# Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

> **NCT01732627** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 301 (actual)

## Conditions studied

- Meningitis
- Meningococcal Meningitis
- Meningococcal Infections
- Invasive Meningococcal Disease

## Interventions

- **BIOLOGICAL:** Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine
- **BIOLOGICAL:** Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined

## Key facts

- **NCT ID:** NCT01732627
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-12
- **Primary completion:** 2013-01-17
- **Final completion:** 2013-01-17
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01732627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01732627, "Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT01732627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*